We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Investigation of a combination therapy approach for the treatment of melioidosis.
- Authors
Barnes, Kay B.; Richards, Mark I.; Burgess, Gary; Armstrong, Stuart J.; Bentley, Christine; Maishman, Thomas C.; Laws, Thomas R.; Nelson, Michelle; Harding, Sarah V.
- Abstract
The efficacy of finafloxacin as a component of a layered defense treatment regimen was determined in vitro and in vivo against an infection with Burkholderia pseudomallei. Doxycycline was down-selected from a panel of antibiotics evaluated in vitro and used in combination with finafloxacin in a Balb/c mouse model of inhalational melioidosis. When treatment was initiated at 24 h post-infection with B. pseudomallei, there were no differences in the level of protection offered by finafloxacin or doxycycline (as monotherapies) when compared to the combination therapy. There was evidence for improved bacterial control in the groups treated with finafloxacin (as monotherapies or in combination with doxycycline) when compared to mice treated with doxycycline. Survival comparisons of finafloxacin and doxycycline (as monotherapies) or in combination initiated at 36 h postinfection indicated that finafloxacin was superior to doxycycline. Doxycycline was also unable to control the levels of bacteria within tissues to the extent that doxycycline and finafloxacin used in combination or finafloxacin (as a sole therapy) could. In summary, finafloxacin is a promising therapy for use in the event of exposure to B. pseudomallei.
- Subjects
MELIOIDOSIS; BURKHOLDERIA infections; BURKHOLDERIA pseudomallei; DOXYCYCLINE; LABORATORY mice
- Publication
Frontiers in Microbiology, 2022, Vol 13, p1
- ISSN
1664-302X
- Publication type
Article
- DOI
10.3389/fmicb.2022.934312